Fig. 5From: Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE studyBenralizumab-induced AER reduction in naïve and bio-experienced patients. Any AER and severe AER are shown at index date and after 48 and 96 weeks after treatment with benralizumabBack to article page